fr   en
Clinical Studies

Browse by date
Or search by keyword
Date: 2010-08-06
Phase: I
Anouncement: Launch
Biotech: Galapagos (Belgium)
Product: GLPG0634 (JAK inhibitor) This orally-available, novel candidate drug is selective against Janus kinase (JAK) 1 and 2 targets discovered in collaboration with GSK. The product was formally part of their arthritis alliance. Galapagos re-acquired the rights to GLPG0634 from GSK for an undisclosed amount and will initiate clinical development of this candidate without any further involvement from GSK.
Disease: arthritis
Country: Belgium
Other: Galapagos is initiating a Phase I clinical trial with the selective JAK inhibitor GLPG0634. The product has been developed by Galapagos and has successfully completed pre-clinical development. Galapagos has received regulatory and ethical committee approval to initiate Phase I clinical studies for GLPG0634 and plans to begin dosing in healthy volunteers on Monday August 9, 2010.
This phase I clinical study will investigate the safety, tolerability and pharmacological profile of GLPG0634. The double blind, placebo-controlled single and multiple ascending dose study will be conducted in at least 40 healthy human volunteers in Belgium over the coming months.
Galapagos aims to maximize the value of GLPG0634 before seeking a partner for development.